SPTX news

Latest 3 stories · newest Nov 2, 2026

SPTX

SPTX reports positive topline data from Phase 1 driving trial

Seaport reported positive topline data from a Phase 1 driving simulation trial of GlyphAllo and dosed the first patient in a Phase 2a trial of GlyphAgo, with cash runway expected to fund operations into 2029.

Earnings|Guidance|Regulatory Nov 2, 2026 sentiment +0.80 SEC filing ↗

SPTX

Seaport Therapeutics reports Q2 2026 results and clinical progress

The company announced full enrollment in its BUOY-1 Phase 2b trial of GlyphAllo for MDD and shared financial highlights, advancing its pipeline of neuropsychiatric therapies.

Earnings Aug 3, 2026 sentiment +0.60 SEC filing ↗

SPTX

Seaport Therapeutics Reports Q1 2026 Results, $260M IPO Proceeds

Seaport Therapeutics reported Q1 2026 financial results and announced new Phase 1 data for GlyphAgo showing therapeutic exposures without liver enzyme elevation concerns. The company's recent upsized IPO generated $260M in gross proceeds, providing funding runway into 2029 while advancing clinical d…

Earnings Jun 8, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same SPTX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/SPTX/newsSTART FREE